Designerx Pharmaceuticals Inc

Designerx Pharmaceuticals Inc. is a subsidiary of Polaris Group, operating as a therapeutic protein drug manufacturer. Based in Vacaville, California, the company employs 11 individuals and generates approximately $8 million in annual revenue. Designerx Pharmaceuticals specializes in producing novel protein therapeutics, primarily focusing on PEGylated Arginine Deiminase (ADI-PEG 20). This lead project is currently undergoing clinical trials for a range of cancers, including hepatocellular carcinoma, non-small cell lung cancer, melanoma, mesothelioma, pancreatic cancer, prostate cancer, leukemia, lymphoma, and breast cancer. Designerx Pharmaceuticals operates a cGMP facility, enabling them to manufacture drugs for clinical trials conducted by Polaris Group across the United States, Europe, and the Asian-Pacific region. For inquiries or further information, please visit Designerx Pharmaceuticals' website at drxpharma.com.